Ignite Creation Date:
2024-05-05 @ 6:46 PM
Last Modification Date:
2024-10-26 @ 9:37 AM
Study NCT ID:
NCT00546624
Status:
COMPLETED
Last Update Posted:
2015-11-01
First Post:
2007-10-17
Brief Title:
GEM 15 mg bid to 45 mg bid Versus Lorazepam in GAD 0777-026
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2015-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will determine the effectiveness of MK0777 GEM versus Lorazepam in the treatment of patients with generalized anxiety disorder
This is an early phase trial and some specific protocol information is in progress and not publicly available at this time Full information is available to trial participants
This is an early phase trial and some specific protocol information is in progress and not publicly available at this time Full information is available to trial participants
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2007_632 | None | None | None |